Melanie Sunderland1, Mandy De Jong, Duane Bates. 1. , BScPharm, ACPR, was, at the time this study was performed, with the Foothills Medical Centre, Alberta Health Services, Calgary, Alberta. She is now a student in the PharmD program at the University of British Columbia, Vancouver, British Columbia.
Abstract
BACKGROUND: Patients with peripheral artery disease are 6 times as likely as healthy individuals to die of cardiovascular causes within 10 years after diagnosis. Combination therapy with a statin, an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), and an antiplatelet agent is recommended to reduce cardiovascular events in patients with peripheral artery disease, especially those with concomitant diabetes mellitus and those who have undergone vascular surgery. OBJECTIVES: The primary objective was to determine the proportion of patients with concurrent diabetes and peripheral artery disease who were receiving therapy with a statin, ACE inhibitor or ARB, and antiplatelet agent (acetylsalicylic acid or clopidogrel) at the time of discharge after vascular surgery. The secondary objectives were to determine if target blood pressure was achieved and if smoking cessation therapy was offered and/or provided. METHODS: This pilot study was a retrospective, cross-sectional chart analysis. The health records database for Alberta Health Services was searched to identify patients with diabetes who underwent vascular surgery at the Foothills Hospital in Calgary with discharge between January 1 and June 30, 2010. In addition to baseline demographic characteristics, blood pressure values at the time of admission and discharge were collected. Discharge medications, including cardiovascular medications such as statins, ACE inhibitor or ARB, and antiplatelet agents, were recorded. Descriptive analysis of the data was performed. RESULTS: Of the 42 patients for whom charts were obtained, 25 (60%) had prescriptions for cardiovascular triple therapy (statin, ACE inhibitor or ARB, antiplatelet agent). Just over half of the patients (23 [55%]) had achieved target blood pressure (< 130/80 mm Hg) at the time of discharge. Of the 14 current smokers, 9 (64%) had documented evidence in the chart that smoking cessation counselling was offered and/or drug therapy was provided. CONCLUSION: Only about half of the patients in this study were receiving cardiovascular triple therapy, which suggests that many patients were not receiving optimal vascular protection. A larger study is needed to review prescribing patterns for patients with peripheral artery disease.
BACKGROUND:Patients with peripheral artery disease are 6 times as likely as healthy individuals to die of cardiovascular causes within 10 years after diagnosis. Combination therapy with a statin, an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB), and an antiplatelet agent is recommended to reduce cardiovascular events in patients with peripheral artery disease, especially those with concomitant diabetes mellitus and those who have undergone vascular surgery. OBJECTIVES: The primary objective was to determine the proportion of patients with concurrent diabetes and peripheral artery disease who were receiving therapy with a statin, ACE inhibitor or ARB, and antiplatelet agent (acetylsalicylic acid or clopidogrel) at the time of discharge after vascular surgery. The secondary objectives were to determine if target blood pressure was achieved and if smoking cessation therapy was offered and/or provided. METHODS: This pilot study was a retrospective, cross-sectional chart analysis. The health records database for Alberta Health Services was searched to identify patients with diabetes who underwent vascular surgery at the Foothills Hospital in Calgary with discharge between January 1 and June 30, 2010. In addition to baseline demographic characteristics, blood pressure values at the time of admission and discharge were collected. Discharge medications, including cardiovascular medications such as statins, ACE inhibitor or ARB, and antiplatelet agents, were recorded. Descriptive analysis of the data was performed. RESULTS: Of the 42 patients for whom charts were obtained, 25 (60%) had prescriptions for cardiovascular triple therapy (statin, ACE inhibitor or ARB, antiplatelet agent). Just over half of the patients (23 [55%]) had achieved target blood pressure (< 130/80 mm Hg) at the time of discharge. Of the 14 current smokers, 9 (64%) had documented evidence in the chart that smoking cessation counselling was offered and/or drug therapy was provided. CONCLUSION: Only about half of the patients in this study were receiving cardiovascular triple therapy, which suggests that many patients were not receiving optimal vascular protection. A larger study is needed to review prescribing patterns for patients with peripheral artery disease.
Authors: Jacques Genest; Ruth McPherson; Jiri Frohlich; Todd Anderson; Norm Campbell; André Carpentier; Patrick Couture; Robert Dufour; George Fodor; Gordon A Francis; Steven Grover; Milan Gupta; Robert A Hegele; David C Lau; Lawrence Leiter; Gary F Lewis; Eva Lonn; G B John Mancini; Dominic Ng; Glen J Pearson; Allan Sniderman; James A Stone; Ehud Ur Journal: Can J Cardiol Date: 2009-10 Impact factor: 5.223
Authors: S Khan; M Flather; R Mister; N Delahunty; G Fowkes; A Bradbury; G Stansby Journal: Eur J Vasc Endovasc Surg Date: 2006-12-29 Impact factor: 7.069
Authors: Alan D Bell; André Roussin; Raymond Cartier; Wee Shian Chan; James D Douketis; Anil Gupta; Maria E Kraw; Thomas F Lindsay; Michael P Love; Neesh Pannu; Rémi Rabasa-Lhoret; Ashfaq Shuaib; Philip Teal; Pierre Théroux; Alexander G G Turpie; Robert C Welsh; Jean-François Tanguay Journal: Can J Cardiol Date: 2011 May-Jun Impact factor: 5.223
Authors: Beth L Abramson; Vic Huckell; Sonia Anand; Tom Forbes; Anil Gupta; Ken Harris; Asad Junaid; Tom Lindsay; Finlay McAlister; Andre Roussin; Jacqueline Saw; Koon Kang Teo; Alexander G Turpie; Subodh Verma Journal: Can J Cardiol Date: 2005-10 Impact factor: 5.223
Authors: Kiran K Kundhal; Siu Lim Chin; Lisa Harrison; Barbara Nowacki; Budhendra Doobay; Jacques Titley; Claudio Ciná; Sonia S Anand Journal: Can J Cardiol Date: 2007-04 Impact factor: 5.223
Authors: Naomi Steenhof; Francesca Le Piane; Kori Leblanc; Naomi R Eisenberg; Yvonne Kwan; Christine Malmberg; Alexandra Papadopoulos; Graham Roche-Nagle Journal: Vasc Health Risk Manag Date: 2014-06-04